Repligen Corporation Investor Presentation — May 2018

Document content

Repligen Corporation

“Inspiring Advances in Bioprocessing”

Craig -Hallum Institutional Investor Conference

May 30, 2018 2 Safe Harbor This presentation contains forward looking statements which are made pursuant to the safe harbor provisions

of Section 27A of the Securities Act of 1933 , as amended, and Section 21E of the Securities Exchange Act of 1934 ,

as amended . These statements are subject to risks and uncertainties which may cause our plans to change or

actual results to differ materially from those anticipated . In particular, unforeseen events outside of our control

may adversely impact future results . Additional information concerning these factors is discussed in our reports

filed with the Securities and Exchange Commission including recent Form 8-Ks, our most recent Annual Report on

Form 10K and our most recent Quarterly report on Form 10Q. The forward looking statements in this

presentation reflect management’s current views and may become obsolete as a result of new information,

future events or otherwise . We may not update such forward looking statements to reflect a change of events or

circumstances that occur after the date hereof, except as required by law. The industry and market data

contained in this presentation are based on management’s own estimates, independent publications,

government publications, reports by market research firms or other published independent sources, and, in each

case, are believed by management to be reasonable estimates . Although we believe these sources are reliable,

we have not independently verified the information . Company Overview 4 Leading

Bioprocessing •Repligen provides innovative bioprocessing technology and solutions to

biologic drug manufacturers worldwide

•We are focused on flexible, disposable and easy -to-implement products

that enable production efficiencies and cost savings

•3 main growth drivers:

Internal innovation,

commercial leverage Acquisitions

strict financial criteria

XCell™ ATF 10 su TangenX TFF cassettes Spectrum KR2 i TFF System 5 Historically

55.7% gross margin 2013 2015 2017

•Direct sales became majority of revenue in 2017: 62% and growing

•Reflects strategic plan, impact of new product development and

acquisitions in our Chromatography and Filtration franchises

Preview truncated — download the full document for the complete content.